Patients (%) | |
---|---|
Total | 63 |
Age | 58 years (range 21 – 81 years) |
Tumor stage | |
FIGO I-II | 13 (20.6) |
FIGO III | 35 (55.6) |
FIGO IV | 15 (23.8) |
Lymph node metastasis | |
N0 | 22 (34.9) |
N1 | 20 (31.7) |
Nx | 21 (33.3) |
Tumor grading | |
I - II | 31 (49.2) |
III - IV | 32 (50.8) |
Histologic subtype | |
serous papillary | Â |
subtype | 50 (79.4) |
other subtypes | 13 (20.6) |
Residual tumor | |
macroscopic | Â |
complete resection | 30 (47.6) |
any residual tumor | 33 (52.4) |
Survival | |
OSa | 36.5 months (range 1 – 70 months) |
Alive | 28 (44.4) |
Dead | 34 (54.0) |
DFSb | 12 months (range 6 – 48 months) |
no relapse | 18 (28.6) |
relapse | 45 (71.4) |
Platinum Resistance | |
Platinum sensitive 54 (85.7) | Â |
Platinum resistant | 9 (14.3) |
DTC c | |
DTC prior to chemotherapy | Â |
Positive | 27 (50.9) |
Negative | 26 (49.1) |
DTC after chemotherapy | Â |
positive | 20 (50.0) |
negative | 20 (50.0) |